JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verwijnen, S. M.
Right arrow Articles by de Jong, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verwijnen, S. M.
Right arrow Articles by de Jong, M.
Journal of Nuclear Medicine Vol. 46 No. 12 2057-2060
© 2005 by Society of Nuclear Medicine


Basic Science Investigations

Oral Versus Intravenous Administration of Lysine: Equal Effectiveness in Reduction of Renal Uptake of [111In-DTPA]Octreotide

Suzanne M. Verwijnen, BSc1, Eric P. Krenning, MD1, Roelf Valkema, MD1, Jan G.M. Huijmans, PhD2 and Marion de Jong, PhD1

1 Department of Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
2 Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands

During tumor therapy with radiolabeled somatostatin analogs, the kidneys are dose limiting. Renal uptake in patients can effectively be reduced by a 4- to 10-h intravenous infusion of a lysine/arginine solution, thereby increasing the maximum radiation dose to the tumor without renal side effects. Oral administration of amino acids could facilitate this labor-intensive procedure. Therefore, the effects of oral versus intravenous administration of D-lysine were compared in rats injected with [111In-diethylenetriaminepentaacetic acid (DTPA)]octreotide. Methods: Rats were intravenously injected with 3 MBq/0.5 µg [111In-DTPA]octreotide and also received D-lysine intravenously or orally in various concentrations and following various time schedules. Twenty-four hours after injection, a biodistribution study and renal ex vivo autoradiography were performed. Results: Renal uptake was reduced significantly—up to 40%—in all lysine-treated groups, without affecting the uptake in other organs. Conclusion: Renal uptake of this radiolabeled peptide can be reduced up to 40% both by oral and by intravenous administration of lysine in rats.

Key Words: peptide receptor radionuclide therapy • kidney reduction • lysine • oral administration


Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 7a-8a. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
M. Gotthardt, J. van Eerd-Vismale, W. J.G. Oyen, M. de Jong, H. Zhang, E. Rolleman, H. R. Maecke, M. Behe, and O. Boerman
Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides
J. Nucl. Med., April 1, 2007; 48(4): 596 - 601.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.